Spotlight On... Shire to take on hemophilia marketing with long-sought Baxalta buy; Walgreens eyes more specialty deals with drugmakers; Sanofi Pasteur's new commercial SVP to keep current agencies; and more...

Baxalta ($BXLT) and its portfolio of hemophilia meds are finally destined to join the fold at Shire ($SHPG). Monday, the two companies announced a $32 billion tie-up after a months-long pursuit by the Dublin drugmaker. More from FiercePharma

> Walgreens ($WBA) it's looking at follow-up specialty pharmacy deals with drugmakers, now that it has sealed a pact with troubled Valeant Pharmaceuticals ($VRX) on a slate of its meds. Report

> Sanofi Pasteur tapped David Loew as its new SVP for global commercial operations; the French drugmaker said its agency relationships won't change, nor will its commercial strategy. Report

> Swedish Orphan Biovitrium said Elocta, a long-acting hemophilia A treatment it developed with Biogen ($BIIB), has been launched in Europe. Release

> Valneva said its Japanese encephalitis vaccine won approval in Taiwan through its partner there, Adimmune. Report

And Finally... A large new study, published in the BMJ, found no risk of birth defects from oral contraceptives. Report

Suggested Articles

Pfizer terminated a slew of trial cohorts testing Bavencio in combination with its own experimental drugs, as well as one monotherapy trial.

NICE rejected Spravato over cost concerns and a lack of head-to-head clinical data against other NICE-recommended alternatives.

Eli Lilly and Incyte are investing heavily in JAK inhibitor Olumiant's chances in atopic dermatitis, but does it stand a chance against Dupixent?